C.H. Robinson Worldwide, Inc. (CHRW) Stock Forecast
Data as of May 2, 2026Industrials · Current price $177.44 (-2.39%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 26, 2026 | Jonathan Chappell | Evercore ISI | $205.00 | +15.5% |
| Feb 2, 2026 | Sergey Glinyanov | Loop Capital Markets | $206.00 | +16.1% |
| Jan 29, 2026 | Jonathan Chappell | Evercore ISI | $219.00 | +23.4% |
| Jan 29, 2026 | Patrick Brown | Raymond James | $215.00 | +21.2% |
| Jan 23, 2026 | Thomas Wadewitz | UBS | $224.00 | +26.2% |
| Jan 8, 2026 | Bascome Majors | Susquehanna | $210.00 | +18.3% |
| Jan 6, 2026 | Christian Wetherbee | Wells Fargo | $185.00 | +4.3% |
| Dec 16, 2025 | Bruce Chan | Stifel Nicolaus | $184.00 | +3.7% |
| Oct 30, 2025 | David Vernon | Bernstein | $135.00 | -23.9% |
| Oct 30, 2025 | Reed Seay | Stephens | $173.00 | -2.5% |
| Oct 30, 2025 | Thomas Wadewitz | UBS | $177.00 | -0.2% |
| Oct 30, 2025 | Patrick Brown | Raymond James | $161.00 | -9.3% |
| Oct 30, 2025 | Fadi Chamoun | BMO Capital | $140.00 | -21.1% |
| Oct 1, 2025 | Richa Harnain | Deutsche Bank | $159.00 | -10.4% |
| Sep 24, 2025 | Bascome Majors | Susquehanna | $160.00 | -9.8% |
| Sep 24, 2025 | Bascome Majors | Susquehanna | $165.00 | -7.0% |
| Jul 31, 2025 | Brandon Oglenski | Barclays | $95.00 | -46.5% |
| Jul 15, 2025 | David Hicks | Raymond James | $111.00 | -37.4% |
| Mar 26, 2025 | Bascome Majors | Susquehanna | $117.00 | -34.1% |
| Jan 10, 2025 | David Hicks | Raymond James | $123.00 | -30.7% |
Top Analysts Covering CHRW
CHRW vs Sector & Market
| Metric | CHRW | Industrials Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.35 | 2.41 | 2.41 |
| Analyst Count | 31 | 8 | 18 |
| Target Upside | +5.6% | +85.0% | +14.9% |
| P/E Ratio | 35.92 | 28.14 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $16.48B | $16.81B | $17.44B | 15 |
| 2027-12-31 | $17.00B | $17.85B | $20.05B | 15 |
| 2028-03-31 | $4.79B | $4.95B | $5.16B | 4 |
| 2028-06-30 | $5.15B | $5.32B | $5.55B | 6 |
| 2028-09-30 | $5.16B | $5.34B | $5.56B | 9 |
| 2028-12-31 | $4.64B | $4.79B | $4.99B | 4 |
| 2029-03-31 | $4.43B | $4.57B | $4.76B | 6 |
| 2029-06-30 | $4.36B | $4.50B | $4.69B | 8 |
| 2029-09-30 | $4.28B | $4.42B | $4.60B | 5 |
| 2029-12-31 | $3.93B | $4.06B | $4.23B | 5 |
| 2030-12-31 | $10.54B | $11.06B | $12.03B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $5.39 | $6.02 | $6.19 | 15 |
| 2027-12-31 | $5.61 | $7.17 | $7.89 | 15 |
| 2028-03-31 | $1.82 | $1.90 | $2.00 | 6 |
| 2028-06-30 | $2.32 | $2.42 | $2.55 | 6 |
| 2028-09-30 | $2.39 | $2.50 | $2.63 | 7 |
| 2028-12-31 | $2.10 | $2.19 | $2.31 | 9 |
| 2029-03-31 | $1.48 | $1.54 | $1.63 | 8 |
| 2029-06-30 | $1.77 | $1.85 | $1.95 | 8 |
| 2029-09-30 | $1.72 | $1.80 | $1.90 | 9 |
| 2029-12-31 | $1.51 | $1.57 | $1.66 | 11 |
| 2030-12-31 | $6.80 | $7.24 | $8.07 | 1 |
Frequently Asked Questions
What is the analyst consensus for CHRW?
The consensus among 31 analysts covering C.H. Robinson Worldwide, Inc. (CHRW) is Buy with an average price target of $184.65.
What is the highest price target for CHRW?
The highest price target for CHRW is $224.00, set by Thomas Wadewitz at UBS on 2026-01-23.
What is the lowest price target for CHRW?
The lowest price target for CHRW is $62.00, set by Ravi Shanker at Morgan Stanley on 2022-02-03.
How many analysts cover CHRW?
31 analysts have issued ratings for C.H. Robinson Worldwide, Inc. in the past 12 months.
Is CHRW a buy or sell right now?
Based on 31 analyst ratings, CHRW has a consensus rating of Buy (2.35/5) with a +5.6% upside to the consensus target of $184.65.
What are the earnings estimates for CHRW?
Analysts estimate CHRW will report EPS of $6.02 for the period ending 2026-12-31, with revenue estimated at $16.81B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.